Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of ...
Compass continues to outperform the real estate market, expanding into new regions and acquiring Christie's real estate ...
As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback